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patients. Adherent patients had lower rate of depression (4.7% vs. 9.5%, P = 0.019), 
higher rate of previous DMD use (49.1% vs. 40.0%, P = 0.032), and higher baseline 
MS-related costs ($4757 vs. $4037, P < 0.001). After adjusting for differences in 
baseline characteristics, DMD adherent patients had lower occurrence of severe 
relapses (12.4% vs. 19.9%, P = 0.013) and lower total (direct and indirect) costs 
($14,095 vs. $16,638, P = 0.048). CONCLUSIONS: Over the two-year study period, 
DMD adherence was associated with signiﬁcantly fewer severe relapses and lower 
total medical costs.
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OBJECTIVES: To assess the contribution of the Zarit score, a measure of perceived 
caregiver burden in Alzheimer’s disease, to health related quality of life as measured 
by the physical and mental component scores of the SF-12 instrument and SF-6D 
health utilities. METHODS: A survey of Alzheimer caregivers was undertaken in the 
US in 2009 (n = 1,079). This survey captured both the characteristics of caregivers 
and the characteristics of the patient to whom the caregiver gave most attention. At 
the same time, caregivers were asked to complete the Zarit burden of care question-
naire and the SF-12 HRQoL instrument. To assess the impact of Zarit scores on 
HRQoL, linear regression (ordinary least squares) models were speciﬁed and estimated 
for the physical and mental component summary scores of the SF-12 and the health 
utility scores from the SF-6D. Independent variables included: caregiver and patient 
characteristics. RESULTS: Average PCS and MCS scores were 47.7 (STD 11.17) and 
42.5 (STD 11.93) respectively; utility score was 0.68 (STD 0.13). Zarit scores were 
distributed with 20.4% of respondents reporting a minimal or no burden, 37.7% a 
mild to moderate burden, 33.1% moderate to severe burden and 8.8% a severe 
burden. Overall16.3% were judged to have mild AD, 53.7% moderate and 30.0% 
severe. Zarit scores played the key role with their greatest impact on the MCS rather 
than the PCS dimensions of the SF-12. In the severe AD category the PCS deﬁcit is 
−5.65 (t = −4.23) compared to a deﬁcit of −17.94 (t = −14.09) for MCS. The corre-
sponding health utility deﬁcit is −0.19 (t = −13.15). Other key variables are caregiver 
age and gender, patient age and gender and living situation. CONCLUSIONS: Per-
ceived caregiver burden is associated primarily with deﬁcits on the mental component 
scores of the SF-12 and on SF-6D health utilities.
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OBJECTIVES: Botulinum Toxin Type-A (BoNTA) is approved for many therapeutic 
indications in Canada, including blepharospasm, 7th cranial nerve disorders, cervical 
dystonia, focal spasticity, cerebral palsy, and hyperhidrosis. Unfortunately, little is 
known about the impact of treatment on health utility. The objective of the ongoing 
national MOBILITY study is to measure the impact of BoNTA on health utility. 
METHODS: Phase IV prospective observational cohort study in patients receiving 
BoNTA for approved therapeutic indications in Canada. Physical component scores 
(PCS), and mental component scores (MCS) are derived from self-reported SF-12v2 
at baseline, week 4 and subsequent clinic visits. Health utility is then measured using 
the SF-6D scoring programme. In this interim analysis continuous data were analyzed 
by student’s t-test and dichotomous data by Chi-square test. RESULTS: To date 917 
patients have been enrolled at 40 clinical sites with a 94.5% retention rate. 69.7% of 
patients returned the week 4 survey and data from 608 individuals were included in 
the analysis (526 were receiving ongoing BOTOX® treatment at baseline; 82 were 
BoNTA-naïve). Signiﬁcant differences were detected in self-reported SF-6D scores 
between baseline and week 4 in the analysis of continuous (p = 0.05) and dichotomized 
data (p = 0.0001), and between baseline and week 4 in the analysis of continuous 
MCS data (p = 0.03). Among BoNTA-naïve patients, there was a statistically signiﬁ-
cant difference in SF-6D scores between baseline and week 4 (p = 0.03 for continuous 
data; p = 0.018 for dichotomized data). There were no statistical signiﬁcant changes 
in the SF-6D scores for patients receiving on-going treatment. CONCLUSIONS: This 
interim analysis from a large ongoing national study shows that signiﬁcant improve-
ments in health utility are obtained in patients receiving BoNTA for therapeutic indica-
tions. Health utility beneﬁt was most pronounced in BoNTA-naive patients as 
evidenced by week 4 MCS scores (the expected peak effect window). Further recruit-
ment and long term follow-up and analyses are ongoing.
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OBJECTIVES: To develop algorithms that convert disease-speciﬁc quality-of-life 
scores for the Headache Impact Test (HIT)-6 and the Migraine Speciﬁc Quality of 
Life, v. 2.1 (MSQ) Questionnaire to health-state utility values derived from the 
EuroQoL-5D (EQ-5D) in chronic migraineurs. METHODS: Data from a cross-sec-
tional multi-country study was used. Chronic migraineurs (ICHD-2 diagnosis of 
migraine and ≥15 headache days/month) completed a series of questions including the 
HIT-6 (n = 547), MSQ (n = 499), and EQ-5D. Subjects were randomly assigned to 
training and validation samples of equal size. Correlations between paired EQ-5D 
index scores and both HIT-6 scores and MSQ domain scores (Role-Restrictive [RR], 
Role-Preventative [RP], and Emotional-Function [EF]) were examined using Spearman 
correlation coefﬁcients. Regression models were constructed to predict EQ-5D utility 
values from the HIT-6 scores or the MSQ domain scores. Preferred algorithms were 
validated using the validation samples. RESULTS: Correlations between the EQ-5D 
index score and the HIT-6 and MSQ dimension scores were statistically signiﬁcant (p 
< 0.001) with correlation coefﬁcients of −0.33 (HIT-6), 0.44 (MSQ-RR), 0.46 (MSQ-
RP), and 0.30 (MSQ-EF). The preferred HIT-6 algorithm was a non-linear model 
which contained a quadratic term for HIT-6, and explained 34% of the variance in 
the training sample. The preferred MSQ algorithm was a linear model with covariates 
representing each domain, and explained 43% of the variance in the training sample. 
Both models also included covariates for age, gender, employment status, headache 
medication use, and comorbidities. In the validation analyses, no statistically signiﬁ-
cant difference was observed between the mean observed EQ-5D score and the mean 
EQ-5D score estimated using the preferred algorithms. CONCLUSIONS: The relation-
ship between the two disease-speciﬁc instruments and the EQ-5D are sufﬁciently 
robust to use regression equations to estimate EQ-5D utility values. These preferred 
models may be useful in estimating health-state utilities in trials of CM patients where 
no preference-based measure is present.
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OBJECTIVES: To evaluate the reliability and validity of the Brief Insomnia Question-
naire (BIQ), a fully-structured measure to assess insomnia based on DSM-IV-TR, 
ICD-10, and RDC criteria. METHODS: The AIS is a large (n = 10,094) epidemiologi-
cal survey of the prevalence and correlates of insomnia in a nationally representative 
sample of managed health care plan subscribers. Probability sub-samples of AIS 
respondents over-sampling BIQ cases completed either short-term test-retest interviews 
(n = 59) or clinical reappraisal interviews (n = 203) to assess BIQ reliability and 
validity. RESULTS: Test-retest correlations were .72–.95 for reports of frequency and 
.47–.94 for reports of severity of sleep problems (initiation, maintenance, non-restor-
ative sleep), .66–.88 for reports of daytime impairment/distress, and .62 for reported 
duration. Good individual-level concordance was found between diagnoses based on 
the BIQ and clinical interviews for meeting criteria in any of the three diagnostic 
systems, with area under the receiver operating characteristic curve (AUC, a measure 
of classiﬁcation accuracy not inﬂuenced by disorder prevalence) of .86 for dichoto-
mous classiﬁcations. AUC increased to .94 when symptom-level data were added to 
generate a continuous measure of predicted probability of clinical diagnosis. AUC was 
lower for dichotomous classiﬁcations based on RDC (.68) and ICD-10 (.70) than 
DSM-IV-TR (.83) criteria, but increased when symptom-level data were added to 
generate continuous measures of predicted probability of diagnoses (.92–.95). CON-
CLUSIONS: The results demonstrate that the BIQ can be used to obtain accurate 
estimates of prevalence and correlates of insomnia in the American Insomnia Survey.
PND24
EVALUATING THE IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON 
NEXT DAY FUNCTIONING
Abraham L1, Lasch KE2, Patrick J3, Piault E2, Tully SE2, Treglia M4
1Pﬁzer Ltd, Sandwich, UK, 2Mapi Values, Boston, MA, USA, 3Pﬁzer, Inc., New London, CT, 
USA, 4Pﬁzer Inc, New London, CT, USA
OBJECTIVES: Symptoms of Restless Legs Syndrome (RLS) typically worsen in the 
early evening and nighttime affecting patients’ quality and duration of sleep which 
can have next day sequelae detrimental to daytime performance. The present qualita-
tive research aimed to support the content validity of a new self-reported outcome 
measure to document the impact of disturbed sleep due to RLS on next day function-
ing. METHODS: An initial conceptual framework was developed based upon a review 
of the literature. The development of the Restless Legs Syndrome—Next Day Impact 
(RLS-NDI) questionnaire included: concept elicitation interviews with 20 clinician-
conﬁrmed idiopathic RLS patients in the US (aged 35–64); grounded theory data 
collection and analysis methods; achievement of saturation; and review by clinical and 
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measurement experts to generate items, responses, and instructions for the new scale. 
Cognitive interviews were conducted with an additional 15 idiopathic RLS patients 
(aged 25–68) to ensure understanding of the new measure, concept comprehensive-
ness, and to identify any necessary revisions to the items and conceptual framework. 
RESULTS: Twenty-three items were generated from patient quotes obtained during 
the concept elicitation interviews. Impacts on next day functioning spontaneously 
attributed to disturbed sleep due to RLS symptoms included: activities of daily living 
(i.e., work, household chores), cognitive functioning (i.e., concentration, forgetfulness, 
mental tiredness, alertness), emotional functioning (i.e., irritability, depressed mood), 
physical functioning (i.e., physical tiredness, active leisure activities), energy, daytime 
sleepiness, and social functioning (i.e., relationships, social activities/situations). 
Concept saturation was achieved. Modiﬁcations to questions and responses were 
based on feedback provided during cognitive interviews. The ﬁnal measure consists 
of 14 items assessed “today” and rated on a severity numeric rating scale. CONCLU-
SIONS: The RLS-NDI is an evaluative tool with demonstrated content validity to 
assess the impact of disturbed sleep due to RLS symptoms on RLS patients’ next day 
functioning.
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OBJECTIVES: Parkinson’s disease (PD) is the second most prevalent neurodegenera-
tive disorder in the US. The Scales for Outcomes in Patients with Parkinson’s disease 
Diary Card (SCOPA-DC) is a daily diary designed to measure motor impairment in 
PD patients with ﬂuctuating symptoms. Consistent with the FDA’s ﬁnal guidance on 
patient-reported outcome measures, this study aimed to evaluate the content validity 
of the SCOPA-DC in the US and determine the feasibility of adding items that measure 
non-motor symptoms using qualitative techniques. METHODS: A literature review 
identiﬁed the most dominant non-motor symptoms experienced by PD patients with 
ﬂuctuating symptoms. Three focus groups were conducted with PD patients (n = 24) 
to identify themes that speciﬁcally addressed the study objectives. The original 
SCOPA-DC was modiﬁed based on ﬁndings from the literature review and patient 
input. A fourth focus group (n = 9) consisted of a cognitive debrieﬁng of the revised 
SCOPA-DC that included additional items and modiﬁed structure based upon the 
previous results. RESULTS: Findings from the focus groups demonstrated support for 
the content of the original SCOPA-DC, generally ﬁnding it to be clear and intuitive, 
despite difﬁculties with some item deﬁnitions, time frames, and response labels. With 
respect to non-motor symptoms, seven domains were consistently mentioned: fatigue, 
concentration/memory, anxiety, pain, difﬁculty swallowing, frequent urination, and 
sweating. The cognitive debrieﬁng focus group reported that the revised SCOPA-DC 
format was easier to use, provided better focus on the items and time frames, and 
more adequately captured experiences throughout the day as compared to the original. 
CONCLUSIONS: Non-motor symptoms occur frequently in PD patients with ﬂuctu-
ating symptoms and have a signiﬁcant impact on health-related quality of life. A 
reliable and validated patient-reported daily diary may improve the ability to describe 
PD progression by accurately measuring both motor and non-motor symptoms. Addi-
tional quantitative research is needed to evaluate the psychometric properties of the 
revised SCOPA-DC.
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OBJECTIVES: To provide evidence for the reliability and validity of the Migraine-
Speciﬁc Quality of Life Questionnaire Version 2.1 (MSQ) for use across migraine 
disorders. METHODS: Cross-sectional data were collected via web-based survey in 
nine countries/regions. Participants were classiﬁed per ICHD-2 criteria as having 
chronic migraine (CM, ≥15 headache days/month), high-frequency episodic migraine 
(HEM, 10–14 headache days/month), or low-frequency episodic migraine (LEM, ≤9 
headache days/month). Three MSQ domains Role Function-Preventive (RP), Role 
Function-Restrictive (RR), and Emotional Function (EF) were rescaled to 0–100, 
where higher scores indicate better health-related quality of life (HRQOL), and ana-
lyzed for internal consistency reliability (Cronbach’s alpha), construct validity (cor-
relations assessed between MSQ scales and measures of depression/anxiety [Patient 
Health Questionnaire; PHQ-4], disability [Migraine Disability Assessment Question-
naire; MIDAS], and functional impact [Headache Impact Test; HIT-6], where lower 
scores indicate better HRQOL for each), as well as discriminant validity across 
migraine groups. RESULTS: A total of 8726 eligible respondents were classiﬁed as 
follows: 5.7% CM (n = 499), 5.9% HEM (n = 515), and 88.4% LEM (n = 7,712). 
Migraineurs were mostly female (83.5%) with a mean (±SD) age of 40.3 ± 11.4, 
similar across the groups. MSQ domain scores for CM, HEM, and LEM groups 
respectively were: RP = 61.4 ± 26.1, 65.9 ± 23.8, and 72.1 ± 23.9; RR = 44.4 ± 22.1, 
48.3 ± 22.8, and 57.0 ± 24.1; EF = 48.3 ± 28.1, 57.8 ± 27.7, and 67.8 ± 26.5. Internal 
consistency of the total sample for RP, RR, and EF was 0.90, 0.96, and 0.87, respec-
tively. Similar values were observed across migraine groups. Varied by domains and 
migraine groups, MSQ scores correlated moderately to highly with scores from the 
PHQ-4 (r = −0.28 to −0.47), MIDAS (r = −0.42 to −0.58), and HIT-6 (r = −0.55 to 
−0.71). Known groups validity indicated signiﬁcant differences (p < 0.0001) in the 
hypothesized direction between CM, HEM, and LEM for RP (F = 58.74), RR (F = 
91.78), and EF (F = 153.38). CONCLUSIONS: The MSQ is a reliable and valid 
questionnaire that can differentiate the functional impact between CM, HEM, and 
LEM.
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OBJECTIVES: The Migraine-Speciﬁc Quality of Life Questionnaire Version 2.1 
(MSQ) is a 14-item health-related quality of life instrument that measures the func-
tional impact of migraine across three domains: Role Function-Preventive (RP), Role 
Function-Restrictive (RR), and Emotional Function (EF). This study evaluated the 
factor structure and cross-cultural comparability of the MSQ in Chronic Migraine 
(CM) sufferers. METHODS: Cross-sectional data were collected via web-based 
survey, across eight countries. Respondents were classiﬁed as having CM per ICHD-2 
criteria with ≥15 headache days/month (n = 499). Conﬁrmatory factor analysis (CFA) 
of the 3-factor model was conducted using the robust maximum likelihood estimator 
(MLR) assuming multivariate normality. Goodness-of-ﬁt was assessed by the com-
parative ﬁt index (CFI), Tucker-Lewis Index (TFI), and root mean square error of 
approximation (RSMEA). Differential item functioning (DIF) was tested using ordinal 
logistic regression of MSQ item scores on group membership and trait level explana-
tory variables. Groups were based on country (Australia, Canada, Germany, Spain, 
France, Great Britain, Italy, United States) and language (English/non-English). Non-
uniform DIF (signiﬁcant interaction term between group membership and trait level, 
p < 0.05) and uniform DIF (>10% change in the trait level coefﬁcient resulting from 
removal of the group membership term from the model) were identiﬁed. RESULTS: 
The 3-factor model demonstrated good ﬁt (CFI = 0.97; TFI = 0.96; RMSEA = 0.07) 
among CM sufferers. Factor loadings ranged between 0.72 and 0.89, and had similar 
values across the three factors. Most MSQ items showed absence of DIF. Non-uniform 
country DIF was identiﬁed in items 5 (inability to concentrate; p = 0.028) and 12 (fed 
up or frustrated; p = 0.037). Item 12 also presented non-uniform DIF related to 
language (p = 0.010). CONCLUSIONS: Among Chronic Migraineurs, the MSQ 
provides a valid measure of RP, RR, and EF, yielding domain scores that can be reli-
ably compared across languages and countries.
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OBJECTIVES: Increasingly health status measures, used to measure the subjective 
functioning and well being of respondents, are being used in trials of treatments which 
are undertaken in a variety of countries. The purpose of this study was to evaluate 
the psychometric properties of a short form health survey, the Parkinson’s Disease 
Questionnaire (PDQ-8), cross-culturally, by comparing results gained from this instru-
ment to the original longer form instrument—the PDQ-39. METHODS: Data are 
from the Global Parkinson’s Disease Survey (GPDS) a cross national survey which 
utilised the thirty nine item Parkinson’s Disease Questionnaire (PDQ-39) as a major 
outcome measure. In this study, we evaluate results from the PDQ-8 (Single Index 
Score PDQ-8-SI) with results from the parent form (from which the PDQ-8 was 
derived), of the instrument in the USA, Canada, Spain, Italy and Japan. RESULTS: 
We evaluate response rate (97% of the 819 respondents completed all items on 
PDQ-8), data quality, score reliability (internal reliability of the eight items of the 
PDQ-8 was calculated for all countries using Cronbach’s alpha, USA = 0.88; Canada 
= 0.83; Italy = 0.87; Spain = 0.79 and Japan = 0.73) and scaling assumptions of the 
instrument in the USA, Canada, Spain, Italy and Japan. CONCLUSIONS: The evi-
dence suggests that PDQ-8-SI seems a useful measure in studies where a short measure, 
providing an overall index of self perceived health in PD, is required. The PDQ-8 is 
a practical and informative instrument for the evaluation of overall quality of life of 
PD patients in cross-cultural studies.
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OBJECTIVES: Bladder dysfunction is a common symptom in patients with multiple 
sclerosis (MS). This study assessed the current literature regarding instruments that 
have been used to measure the health-related quality of life (HRQOL) impact of this 
chronic illness, and to what extent bladder dysfunction affects HRQOL in this popula-
tion. METHODS: Two searches using MEDLINE/PubMed’s MeSH database were 
made. Quality of life was isolated by checking the psychology subheading within the 
